Crossref
Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
Haematology International Journal · 2017
DOI: 10.23880/hij-16000106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haematology International Journal, 2017. Verfasst von Monia Marchetti.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Marchetti, M. (2017). Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia. Haematology International Journal. https://doi.org/10.23880/hij-16000106
Vancouver
Marchetti M. Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia. Haematology International Journal. 2017. doi:10.23880/hij-16000106
BibTeX
@article{Marchetti2017,
author = {Marchetti, Monia},
title = {Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia},
journal = {Haematology International Journal},
year = {2017},
doi = {10.23880/hij-16000106}
}
EUVIMED